← Eichor
Study identifier: NCT07483658 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Condition: Reccurent/Metastatic Solid Tumor Disease · Prostate Cancer (Post Prostatectomy) · Prostate Cancer  ·  Sponsor: CHU de Quebec-Universite Laval

PhaseNA
Planned participants434
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA). The goal is to see if a shorter treatment schedule is as safe and effective as the standard schedule. Why is this study important? After prostate surgery, cancer can return in up to 70-80% of high-risk patients. Radiotherapy helps control this, but the best way to deliver it-especially the number of sessions and whether to treat the pelvic area-is still being studied. Shorter treatments could mean less time in therapy and better quality of life, if such treatments are proven safe. What is being compared? Standard treatment (Arm A): 25 sessions (about 5 weeks) Prostate bed: 62.5 Gy Pelvis: 45 Gy Shorter treatment (Arm B): 20 sessions (about 4 weeks) Prostate bed: 52.5 Gy Pelvis: 43 Gy Both groups may also receive hormone therapy (ADT) for 6-24 months. Main Goal To check if the shorter treatment causes no more side effects (urinary or bowel problems) than the standard treatment, while keeping cancer control similar. Other Things to be Measured Cancer control (PSA levels, spread of disease) Survival Quality of life (urinary, bowel, sexual health questionnaires) Who can join? Men who: Had prostate surgery Have a detectable PSA (≥0.2 ng/mL) No distant metastasis Are in good general health (ECOG 0-2) How long will the study last? About 12 years total: 2 years to enroll patients 1…

This description comes directly from the study's public registry record.

Talk to the study team

Eric Vigneault, MD, MSc  ·  418 691-5264  ·  eric.vigneault.med@ssss.gouv.qc.ca

Damien Carignan, PhD  ·  418 525-4444  ·  damien.carignan@crchudequebec.ulaval.ca

Always discuss trial participation with your own doctor first.

Locations (4)

Gatineau HospitalGatineau, Quebec, CanadaNot Yet Recruiting
Hôpital Général JuifMontreal, Quebec, CanadaNot Yet Recruiting
McGill University Health CentreMontreal, Quebec, CanadaNot Yet Recruiting
CHU de Québec-Université LavalQuébec, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07483658